- Home
- CLSD vs CNTX Comparison
CLSD vs CNTX Comparison
Compare CLSD & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSD
- CNTX
- Stock Information
- Founded
- CLSD 2011
- CNTX 2015
- Country
- CLSD United States
- CNTX United States
- Employees
- CLSD N/A
- CNTX N/A
- Industry
- CLSD Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLSD Health Care
- CNTX Health Care
- Exchange
- CLSD Nasdaq
- CNTX Nasdaq
- Market Cap
- CLSD 69.0M
- CNTX 78.0M
- IPO Year
- CLSD 2016
- CNTX 2021
- Fundamental
- Price
- CLSD $0.76
- CNTX $0.58
- Analyst Decision
- CLSD Strong Buy
- CNTX Strong Buy
- Analyst Count
- CLSD 5
- CNTX 4
- Target Price
- CLSD $4.80
- CNTX $6.00
- AVG Volume (30 Days)
- CLSD 161.6K
- CNTX 164.6K
- Earning Date
- CLSD 05-14-2025
- CNTX 05-07-2025
- Dividend Yield
- CLSD N/A
- CNTX N/A
- EPS Growth
- CLSD N/A
- CNTX N/A
- EPS
- CLSD N/A
- CNTX N/A
- Revenue
- CLSD $3,764,000.00
- CNTX N/A
- Revenue This Year
- CLSD N/A
- CNTX N/A
- Revenue Next Year
- CLSD $476.77
- CNTX N/A
- P/E Ratio
- CLSD N/A
- CNTX N/A
- Revenue Growth
- CLSD N/A
- CNTX N/A
- 52 Week Low
- CLSD $0.70
- CNTX $0.49
- 52 Week High
- CLSD $1.65
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CLSD 34.26
- CNTX 27.74
- Support Level
- CLSD $0.77
- CNTX $0.66
- Resistance Level
- CLSD $0.91
- CNTX $0.71
- Average True Range (ATR)
- CLSD 0.06
- CNTX 0.08
- MACD
- CLSD -0.01
- CNTX -0.02
- Stochastic Oscillator
- CLSD 5.82
- CNTX 24.19
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.